ES2584161T3 - Uso de dimiracetam en el tratamiento del dolor crónico - Google Patents
Uso de dimiracetam en el tratamiento del dolor crónico Download PDFInfo
- Publication number
- ES2584161T3 ES2584161T3 ES14004202.9T ES14004202T ES2584161T3 ES 2584161 T3 ES2584161 T3 ES 2584161T3 ES 14004202 T ES14004202 T ES 14004202T ES 2584161 T3 ES2584161 T3 ES 2584161T3
- Authority
- ES
- Spain
- Prior art keywords
- dimiracetam
- treatment
- chronic pain
- test
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002193 Pain Diseases 0.000 title abstract description 4
- XTXXOHPHLNROBN-UHFFFAOYSA-N dimiracetam Chemical compound N1C(=O)CN2C1CCC2=O XTXXOHPHLNROBN-UHFFFAOYSA-N 0.000 title abstract description 4
- 229950002911 dimiracetam Drugs 0.000 title abstract description 4
- 208000000094 Chronic Pain Diseases 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 229940124977 antiviral medication Drugs 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 7
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 238000012453 sprague-dawley rat model Methods 0.000 description 4
- 208000004454 Hyperalgesia Diseases 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 3
- 229960001756 oxaliplatin Drugs 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000770A ITMI20070770A1 (it) | 2007-04-16 | 2007-04-16 | Impiego di dimiracetam nel trattamento del dolore cronico |
| ITMI20070770 | 2007-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2584161T3 true ES2584161T3 (es) | 2016-09-26 |
Family
ID=39628738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14004202.9T Active ES2584161T3 (es) | 2007-04-16 | 2008-04-15 | Uso de dimiracetam en el tratamiento del dolor crónico |
| ES08749565.1T Active ES2536631T3 (es) | 2007-04-16 | 2008-04-15 | Uso de dimiracetam en el tratamiento de dolor crónico |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08749565.1T Active ES2536631T3 (es) | 2007-04-16 | 2008-04-15 | Uso de dimiracetam en el tratamiento de dolor crónico |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7989421B2 (enExample) |
| EP (3) | EP2146706B1 (enExample) |
| JP (1) | JP5409602B2 (enExample) |
| CN (2) | CN103284997B (enExample) |
| AU (1) | AU2008237901B2 (enExample) |
| BR (1) | BRPI0810475A2 (enExample) |
| CA (1) | CA2684363C (enExample) |
| EA (2) | EA019354B1 (enExample) |
| ES (2) | ES2584161T3 (enExample) |
| IL (2) | IL201498A (enExample) |
| IT (1) | ITMI20070770A1 (enExample) |
| MX (1) | MX2009011380A (enExample) |
| PL (2) | PL2857017T3 (enExample) |
| WO (1) | WO2008125674A1 (enExample) |
| ZA (1) | ZA200906991B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9125898B2 (en) | 2008-11-14 | 2015-09-08 | Neurotune Ag | Acetam derivatives for pain relief |
| PL2598504T3 (pl) | 2010-07-26 | 2014-10-31 | Neurotune Ag | Sposób otrzymywania dimiracetamu |
| EP2658540A1 (en) * | 2010-10-29 | 2013-11-06 | Neurotune AG | Therapeutic use of dimiracetam to prevent the hand&foot syndrome caused by sorafenib |
| JPWO2012137645A1 (ja) * | 2011-04-07 | 2014-07-28 | 旭化成ファーマ株式会社 | 抗癌剤に起因する異痛症の予防及び／又は治療剤 |
| CN102743372B (zh) * | 2012-06-30 | 2015-09-09 | 江苏省中医药研究院 | 一种化疗致血痹动物模型建立方法 |
| JOP20190251A1 (ar) * | 2017-05-31 | 2019-10-21 | Metys Pharmaceuticals AG | تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية |
| MX2020005310A (es) * | 2017-11-21 | 2020-10-08 | Medoncare Pharmaceutical Co Ltd | Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo. |
| DE102019107619A1 (de) | 2019-03-25 | 2020-10-01 | Mondi Ag | Verpackungsbeutel aus einem Kunststoffgewebeverbund |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3324219A1 (de) * | 1983-07-05 | 1985-01-17 | Hoechst Ag, 6230 Frankfurt | Mehrlagige elektroisolierfolie |
| US5028595A (en) * | 1987-09-18 | 1991-07-02 | Hoffmann-La Roche Inc. | Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus |
| IT1233860B (it) | 1988-02-08 | 1992-04-21 | Isf Spa | Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa |
| GB9123641D0 (en) | 1991-11-07 | 1992-01-02 | Isf Spa | Process |
| CA2392879C (en) * | 1999-12-01 | 2005-03-29 | Ucb, S.A. | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders |
| KR100823668B1 (ko) * | 2000-12-28 | 2008-04-21 | 해밀턴 파마슈티컬스 인코포레이티드 | 신경성 통증 치료 및 예방약 |
| ITMI20030573A1 (it) * | 2003-03-24 | 2004-09-25 | Nikem Research Srl | Composti ad azione nootropica, loro preparazione, |
-
2007
- 2007-04-16 IT IT000770A patent/ITMI20070770A1/it unknown
-
2008
- 2008-04-15 MX MX2009011380A patent/MX2009011380A/es active IP Right Grant
- 2008-04-15 ES ES14004202.9T patent/ES2584161T3/es active Active
- 2008-04-15 US US12/450,944 patent/US7989421B2/en active Active
- 2008-04-15 EP EP08749565.1A patent/EP2146706B1/en active Active
- 2008-04-15 JP JP2010503482A patent/JP5409602B2/ja active Active
- 2008-04-15 PL PL14004202.9T patent/PL2857017T3/pl unknown
- 2008-04-15 CN CN201310182360.3A patent/CN103284997B/zh not_active Expired - Fee Related
- 2008-04-15 EP EP14004202.9A patent/EP2857017B1/en active Active
- 2008-04-15 CA CA2684363A patent/CA2684363C/en not_active Expired - Fee Related
- 2008-04-15 BR BRPI0810475A patent/BRPI0810475A2/pt not_active IP Right Cessation
- 2008-04-15 PL PL08749565T patent/PL2146706T3/pl unknown
- 2008-04-15 CN CN200880015837A patent/CN101677984A/zh active Pending
- 2008-04-15 EP EP13002151.2A patent/EP2620149A3/en not_active Withdrawn
- 2008-04-15 WO PCT/EP2008/054553 patent/WO2008125674A1/en not_active Ceased
- 2008-04-15 EA EA200901237A patent/EA019354B1/ru not_active IP Right Cessation
- 2008-04-15 EA EA201300826A patent/EA022867B1/ru not_active IP Right Cessation
- 2008-04-15 ES ES08749565.1T patent/ES2536631T3/es active Active
- 2008-04-15 AU AU2008237901A patent/AU2008237901B2/en not_active Ceased
-
2009
- 2009-10-07 ZA ZA2009/06991A patent/ZA200906991B/en unknown
- 2009-10-13 IL IL201498A patent/IL201498A/en active IP Right Grant
-
2011
- 2011-06-22 US US13/166,088 patent/US8222241B2/en active Active
-
2012
- 2012-03-26 IL IL218851A patent/IL218851A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003462A (es) | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). | |
| JP2015110588A5 (enExample) | ||
| MX2020003421A (es) | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). | |
| ATE511392T1 (de) | Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| MX377576B (es) | Formulaciones de pridopidina de liberación modificada. | |
| MX2010003642A (es) | Nanotecnologia de vacuna. | |
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| JP2012533565A5 (enExample) | ||
| NZ715686A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| FI3044229T3 (fi) | Peptidejä käytettäväksi suun limakalvotulehduksen hoidossa | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| JP2019534265A5 (ja) | 医薬組成物およびその投与方法 | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| EA201791138A1 (ru) | Фармацевтическая композиция, ее приготовление и применения | |
| MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| ES2663836T3 (es) | Carboxamidas de quinolina para su uso en el tratamiento de leucemia | |
| RU2006115784A (ru) | Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта | |
| MX389088B (es) | Métodos para tratar el vhc. | |
| FI3442538T3 (fi) | Levodopan aiheuttaman dyskinesian hoito trapidiililla | |
| MX2023012198A (es) | Composiciones de amantadina, preparaciones de estas y metodos de uso. | |
| JP2014148552A5 (enExample) | ||
| WO2019147338A3 (en) | Radiopharmaceuticals and methods of use thereof |